April 18th 2024
Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Elizabeth Plimack, MD, MS, Talks Risk Categories in KEYNOTE-426 Trial on Advanced RCC
June 14th 2020Elizabeth Plimack, MD, MS, discussed the analysis of risk categories for patients included in the KEYNOTYE-426 trial investigating axitinib and pembrolizumab over sunitinib for patients with advanced renal cell carcinoma.
Elizabeth Plimack, MD, MS, Discusses Subsequent Therapy in Advanced RCC
June 9th 2020Elizabeth Plimack, MD, MS, discussed the role of subsequent immunotherapy when analyzing the primary endpoint of overall survival for axitinib and pembrolizumab over sunitinib in patients with advanced renal cell carcinoma evaluated in the updated analysis of KEYNOTE-426.
Kidney Cancer Destination Could Guide Treatment Decisions Moving Forward
April 27th 2020A recent study examined pancreatic metastases to understand why patients with this particular kidney cancer have better prognoses, and sought to characterize the clinical behavior, therapeutic implications, and underlying biology of this type of cancer.
Phase III CheckMate-9ER Trial Meets Primary Endpoint in Advanced RCC Trial
April 21st 2020The trial evaluated nivolumab in combination with cabozantinib compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma, meeting its primary endpoint of progression-free survival at final analysis.
AYAs with Certain Cancer Types Saw Improvements in 5-Year Mortality Rates
March 11th 2020A study showed that adolescents and young adults with certain types of cancers saw significant improvements in their 5-year mortality rates, while other cancer types saw little to no significant improvement among the same demographic group.
Renal Function Change Found to be a Prognostic Factor for Cancer Specific Survival in RCC
February 9th 2020The aim of this Chinese study was to evaluate the influencing factors of perioperative renal function change and their relationship with prognosis in patients with renal cell carcinoma and tumor thrombus after nephrectomy and thrombectomy.